ESMO 2023 |  Dr. Manuela Schmidinger: Research progress in the treatment of Renal cell carcinoma

ESMO 2023 |  Dr. Manuela Schmidinger: Research progress in the treatment of Renal cell carcinoma

Renal cell carcinoma (RCC), a type of kidney cancer, has been the focus of extensive research in recent years. The recent advancements in the treatment of renal cell carcinoma have provided new hope for patients with this challenging disease.  As research continues, it is crucial to individualize treatment strategies based on patient risk profiles and explore novel approaches to address the specific needs of different RCC subtypes. Further research and clinical trials will undoubtedly continue to refine and expand our understanding of these groundbreaking therapies, with the ultimate goal of enhancing the quality of life and survival rates for individuals battling RCC.
ESMO 2023 | Dr. Silke Gillessen: Biomarkers and Future Perspectives in Advanced Prostate Cancer

ESMO 2023 | Dr. Silke Gillessen: Biomarkers and Future Perspectives in Advanced Prostate Cancer

Prostate cancer, a multifaceted disease, frequently progresses to an advanced stage, imposing substantial therapeutic challenges. This advanced phase comprises both metastatic and locally advanced forms, demanding innovative strategies for effective management. In recent years, the discovery and application of biomarkers have emerged as a pivotal driving force in guiding treatment decisions and elevating patient outcomes. This article will delve deeper into the fundamental challenges surrounding advanced prostate cancer, the pivotal role of biomarkers in determining treatment pathways, the utility of cutting-edge imaging techniques, and the exciting prospects of biomarker-based therapies.
ESMO 2023: Advancements in Oncology, Honoring Excellence, and the Global Impact

ESMO 2023: Advancements in Oncology, Honoring Excellence, and the Global Impact

ESMO 2023: Advancements in Oncology, Honoring Excellence, and the Global Impact The European Society for Medical Oncology (ESMO) 2023 Congress held in Madrid was a momentous event that brought together oncology professionals and researchers from across the globe. This comprehensive article delves into the key highlights of this remarkable event, encapsulating the essence of the President's speech, WHO officials' insights, the Scientific Chair's vision, the issuance of prestigious ESMO Awards, and the thought-provoking speeches delivered by each ESMO Award-winning expert. It's an exploration of the evolving landscape of oncology, the global fight against cancer, and the exceptional contributions of individuals in the field.
Interview with Dr. Girard Deciphers at ELCC 2023

Interview with Dr. Girard Deciphers at ELCC 2023

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.
2023 SGBCC Expert Voting: Radiotherapy

2023 SGBCC Expert Voting: Radiotherapy

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, known as the "City of Music", from March 15th to 18th, 2023, local time. SGBCC brought together breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics regarding early-stage breast cancer treatment. This culminates in the St.Gallen early-stage breast cancer international expert consensus, which is updated every two years. On the last day of the conference, the expert voting was the highlight. 
2023 SGBCC Expert Voting: Endocrine Therapy and Chemotherapy Decision for ER-Positive Breast Cancer

2023 SGBCC Expert Voting: Endocrine Therapy and Chemotherapy Decision for ER-Positive Breast Cancer

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "World Music Capital," from March 15 to 18, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in early breast cancer diagnosis and treatment, forming an updated St.Gallen International Expert Consensus on Early Breast Cancer every two years. On the final day of the conference, expert voting took center stage. Oncology Frontier  has compiled expert votes on two topics: adjuvant endocrine therapy and chemotherapy decisions for ER-positive breast cancer.
2023 SGBCC Expert Voting: Pathology, Genes, DCIS, Male Breast Cancer

2023 SGBCC Expert Voting: Pathology, Genes, DCIS, Male Breast Cancer

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "City of Music", from March 15 to 18, 2023 local time. SGBCC gathered breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics related to early-stage breast cancer treatment. This forms the St.Gallen Early Breast Cancer International Expert Consensus, which is updated every two years. "Oncology Frontier" has compiled expert votes on topics related to early breast cancer's pathology, genes, DCIS, and male-related issues. Let's experience the St.Gallen atmosphere of early breast cancer treatment decision-making.
2023 SGBCC Expert Voting: HER2 Positive, BRCA Associated,  Bone Modifying Therapy, Molecular Diagnosis

2023 SGBCC Expert Voting: HER2 Positive, BRCA Associated,  Bone Modifying Therapy, Molecular Diagnosis

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, known as the "Capital of World Music", from March 15th to 18th, 2023 local time. On the last day of the conference, the highlight was the expert voting session. Oncology Frontier  has  compiled expert voting on the treatment of HER2 positive breast cancer, BRCA Associated treatment,  Bone Modifying Therapy , oligo-metastatic disease, and molecular diagnosis topics. Additionally, a selection of these topics was presented for readers to vote on, allowing them to immerse themselves in the St.Gallen atmosphere of early breast cancer treatment decision-making.
WCLC 2023 : Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

WCLC 2023 : Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

On the final day of the 2023 World Conference on Lung Cancer (WCLC) , Oncology Frontier  had the privilege of interviewing Dr. Wu Yilong from Guangdong Provincial People's Hospital, Dr. Cheng Ying from Jilin Cancer Hospital, and Dr. Han Baohui from Shanghai Chest Hospital. These three experts participated in a dialogue and discussion regarding hot topics at the conference and significant clinical research. Here present the highlights of their on-site discussions.
WCLC 2023 | Dr. Liu: Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

WCLC 2023 | Dr. Liu: Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in ES-SCLC patients. Oncology Frontier invited Dr. Liu to highlight his presentation at the conference.